Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02270944 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,053
- Enrollment target
NCT02270944 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,053 participants.
The verdict
NCT02270944, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,053 participants
- Enrollment target
Study Summary
The purpose of the present study is to assess and compare in healthy non-pregnant women 18 to 40 years of age the safety and immunogenicity of a liquid formulation of Group B Streptococcus (GBS) Trivalent Vaccine (not requiring reconstitution prior to administration), and of the lyophilized formulation of GBS Trivalent Vaccine, administered in non-pregnant and pregnant women in the clinical development program to date.
Interventions
- BIOLOGICAL GBS Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,053 participants |
| Start Date | 2014-11-20 |
| Est. Completion | 2015-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02270944
The ClinicalTrials.gov registry entry for NCT02270944 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,053 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GBS Vaccine is the first listed.
NCT02270944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02270944 about?
NCT02270944 is a clinical study titled "Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine". The purpose of the present study is to assess and compare in healthy non-pregnant women 18 to 40 years of age the safety and immunogenicity of a liquid formulation of Group B Streptococcus (GBS) Trivalent Vaccine (not requiring reconstitution prior to administration), and of the lyophilized formulat...
What is the current status of trial NCT02270944?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,053 participants. The study started on 2014-11-20. Estimated completion is 2015-09-22.
What interventions are being tested in trial NCT02270944?
The interventions under investigation include: GBS Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02270944?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.